Press Releases - Cohance

Show More

Select Year

12th August 2025

Press Release_ Investment in cGMP Bioconjugation Suite at NJ Bio...

VIEW DETAILS →

12th August 2025

Press Release_Investment and Progress on cGMP Oligonucleotide...

VIEW DETAILS →

29th July 2025

Cohance Lifesciences Appoints Yann D'Herve as CEO of CDMO Business

VIEW DETAILS →

7th May 2025

Press Release regarding change in name of the Company ...

VIEW DETAILS →

25th April 2025

Press Release – Effective date for Scheme of Amalgamation ...

VIEW DETAILS →

7th March 2025

US FDA completes surveillance inspection of Cohance Life Sciences’ API ...

VIEW DETAILS →

7th December 2024

Suven to acquire controlling stake in NJ Bio, Inc., an ADC specialist ...

VIEW DETAILS →

19th September 2024

Suven Pharmaceuticals names Mr. Vivek Sharma as ExecutiveChairman ...

VIEW DETAILS →

9th August 2024

Suven Pharmaceuticals announces Q1 FY25 financial results ...

VIEW DETAILS →

13th June 2024

Suven to acquire a majority stake in an oligonucleotide focused ...

VIEW DETAILS →

30th May 2024

Suven Pharmaceuticals Announces Full-Year FY24 Results ....

VIEW DETAILS →

29th February 2024

Suven Announces Merger of Cohance Lifesciences, Forging ...

VIEW DETAILS →

5th February 2024

Suven Pharma reports FY24 third quarter and nine months ...

VIEW DETAILS →

2024

Suven Pharma reports FY24 second quarter and half yearly financial results ...

VIEW DETAILS →

Top